ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Summary

In this research study, is combining a new treatment acalabrutinib with a standard treatment, rituximab or other CD20 antibody, to determine whether this combination is safe and effective for participants with Immunoglobulin (Ig) M monoclonal gammopathy of undetermined significance ( IgM MGUS) or Waldenström macroglobulinemia WM related neuropathies. The names of the study drugs involved in this study are/is: * Acalabrutinib * Rituximab or similar CD20 antibody

Timeline

Start

2021-11-16

Primary completion

2026-12-01

Completion

2028-10-01

Publications

• Nardin J, Dittus C, Traub R. Clinical and Electrodiagnostic Findings in Anti-myelin-Associated Glycoprotein Antibody Polyneuropathy: A Single Center Review. J Clin Neuromuscul Dis. 2025 Jun 2;26(4):200-205. doi: 10.1097/CND.0000000000000525.

Drugs

Indications